Abstract | INTRODUCTION: Current available treatments for inflammatory bowel disease (IBD) have some limitations and new options are needed. Several new molecules are being tested for the treatment of IBD and other immune-mediated inflammatory diseases. Among them, Janus kinase ( JAK) inhibitors seem to have the lead, since tofacitinib has received regulatory approval in 2012 for the treatment of rheumatoid arthritis, and also it has shown a favorable risk-benefit ratio in phase 3 studies for ulcerative colitis, both in anti-TNF naïve and anti-TNF experienced patients. Other compounds with JAK inhibitory activity are also being tested with promising results. Areas covered: This review discusses the molecular aspects of the JAK-STAT pathway, which gives rationale for the use of JAK inhibitors in immune-mediated inflammatory diseases, especially in IBD. Different compounds with JAK inhibitory activity are presented, and relevant efficacy and safety data in IBD and other conditions are discussed. Expert commentary: It would not be surprising that in a foreseeable future many new orally administrated drugs will be available. This enhanced armamentarium will probably pose new dilemmas, in terms of drug positioning, escalation and de-escalation strategies, and combination therapy.
|
Authors | Pablo Olivera, Silvio Danese, Laurent Peyrin-Biroulet |
Journal | Expert review of clinical immunology
(Expert Rev Clin Immunol)
Vol. 13
Issue 7
Pg. 693-703
(07 2017)
ISSN: 1744-8409 [Electronic] England |
PMID | 28164724
(Publication Type: Journal Article, Review)
|
Chemical References |
- Piperidines
- Protein Kinase Inhibitors
- Pyrimidines
- Pyrroles
- STAT Transcription Factors
- tofacitinib
- Janus Kinases
|
Topics |
- Animals
- Arthritis, Rheumatoid
(drug therapy)
- Clinical Trials as Topic
- Humans
- Inflammatory Bowel Diseases
(drug therapy)
- Janus Kinases
(antagonists & inhibitors)
- Molecular Targeted Therapy
- Piperidines
(therapeutic use)
- Protein Kinase Inhibitors
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Pyrroles
(therapeutic use)
- Risk Assessment
- STAT Transcription Factors
(metabolism)
- Signal Transduction
|